Moleculin Biotech Inc. (NASDAQ: MBRX) Attends 31st Annual ROTH Conference
Moleculin Biotech (NASDAQ: MBRX) is a clinical-stage pharmaceutical company focused on development of oncology drug candidates based on discoveries at M.D. Anderson Cancer Center. The company’s clinical-stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML); and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. Moleculin Biotech is also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors. For more information, visit the company's website at…







